Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease by Bucossi, Serena et al.
SAGE-HindawiAccess to Research
International Journal of Alzheimer’s Disease
Volume 2011, Article ID 973692, 9 pages
doi:10.4061/2011/973692
Research Article
Associationbetween thec.2495A>G ATP7B Polymorphism and
Sporadic Alzheimer’s Disease
SerenaBucossi,1,2 StefaniaMariani,1,2 MariacarlaVentriglia,1,2 RenatoPolimanti,3
Massimo Gennarelli,4 CristianBonvicini,4 PatrizioPasqualetti,2 Federica Scrascia,1
Simone Migliore,2 FabrizioVernieri,1 Paolo M.Rossini,1,5 and RosannaSquitti1,2
1Department of Neurology, Campus Bio-Medico University of Rome, 00128 Rome, Italy
2Department of Neuroscience, AFaR-Fatebenefratelli Hospital, 00186 Rome, Italy
3Department of Biology, Tor Vergata University of Rome, 00173 Rome, Italy
4Genetics Unit, IRCCS San Giovanni di Dio-Fatebenefratelli, 25125 Brescia, Italy
5Department of Imaging, San Raﬀaele Cassino, 03043 Cassino FR, Italy
Correspondence should be addressed to Serena Bucossi, s.bucossi@unicampus.it
Received 30 December 2010; Accepted 1 April 2011
Academic Editor: D. Larry Sparks
Copyright © 2011 Serena Bucossi et al.This isanopen accessarticledistributed undertheCreative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Nonceruloplasmin-bound copper (“free”) is reported to be elevated in Alzheimer’s disease (AD). In Wilson’s disease (WD) Cu-
ATPase 7B protein tightly controls free copper body levels.To explore whether the ATP7B gene harbours susceptibility loci forAD,
we screened 180 AD chromosomes for sequence changes in exons 2, 5, 8, 10, 14, and 16, where most of the Mediterranean WD-
causing mutations lie. No WD mutation, but sequence changes corresponding to c.1216 T>G Single-Nucleotide Polymorphism
(SNP) and c.2495 A>G SNP were found. Thereafter, we genotyped 190 AD patients and 164 controls for these SNPs frequencies
estimation.Logisticregression analyses revealed either a trend for the c.1216 SNP (P = .074) or a higher frequency for c.2495 SNP
o ft h eG Gg e n o typ ei np a t i e n t s ,i n c r e a s i n gt h ep r o b a b i l i tyo fA Db y7 4 %( P = .028).Presence oftheGG genotype in ATP7B c.2495
could account for copper dysfunction in AD which has been shown to raise the probability of the disease.
1.Introduction
There is a general agreement on the existence of a link
between Alzheimer’s disease (AD) and oxidative stress phe-
nomenatriggeredbytransitionmetals[1,2].Theexistenceof
systemic copper dysfunctions in AD has been a controversial
issue for many years. In fact, many studies have reported an
increase of circulating copper in AD patients with respect
to healthy controls [3–13], many others no variation [14–
23], and two very recent studies even a decrease of plasma
[24]a n ds e r u m[ 25] copper in AD patients. Recently,
to gain an objective evaluation to the question whether
systemic copper variations are associated to AD a meta-
analysis of all the studies carried out on serum/plasma
copper in AD and healthy cohorts between 1983 and 2010
was run [26]. This analysis demonstrated that AD patients
have higher levels of serum Cu than healthy controls. Even
though moderate, the assessed copper increase was suﬃcient
to unambiguously distinguish AD patients from healthy
controls.
Abnormalities in serum copper not bound to ceruloplas-
min (“free” copper [27]) can be advocated as an explanatory
variable of copper disturbances in AD [26, 28], as several
research groups recently conﬁrmed [3, 25, 29, 30]. Normally,
most human serum copper binds tightly to ceruloplasmin
[27]. The remaining copper, that is free copper, is distributed
and exchanged among albumin, alpha 2 macroglobulin,
and low-molecular-weight compounds such as peptides and
amino acids (e.g., histidine [31]. A key diﬀerence between
the two pools lies in the fact that the low-molecular-weight
compounds allow free copper to easily cross the Blood-
Brain Barrier (BBB) [32, 33]. A recent study conﬁrmed the
evidence that the copper transport into the brain is mainly
achieved through the BBB as free copper ion, and the blood-
cerebrospinalﬂuidbarriermayserveasamain regulatorysite
of copper in the cerebrospinal ﬂuid (CSF) [34].2 International Journal of Alzheimer’s Disease
Wilson’s disease is the paradigmatic example of copper
toxicosis or accumulation, in which large amounts of free
copper enter the brain and cause cognitive impairment
[35, 36], abnormal glial cells and degenerated ganglion
cells in cerebral cortex, putamen, and dentate nucleuses
[35, 36]. In WD, free copper levels are disproportionately
high due to defects in the ATPase 7B (WD protein) and
represent most of the circulating copper. Systemic copper
abnormalitiesinADresemblethoseobservedinWD,though
they are very much less severe [10, 37]. Moreover, free
copper correlates with the typical deﬁcits [9, 38–40]a n d
markers of AD, namely, CSF Amyloid Beta (Aβ)a n dT a u
proteins [9], as well as an unfavourable prognosis of the
disease [40], and tend to predict the annual worsening in
Minimental State Examination (MMSE) [10, 41]. WD is
an autosomal recessive genetic disorder due to mutations
i nt h eA T P 7 Bg e n e( W Dg e n e ) ,a n dt h er a t eo fo c c u r r e n c e
of a single abnormal copy is 1 in 90 people [36]. Based
on this, we initiated a hypothesis-driven candidate gene
project to determine whether the WD ATP7B gene harbours
susceptibility loci for late-onset AD [42, 43]. In particular, in
the study presented, we explored the hypothesis that ATP7B
sequence changes in exon 2, 5, 8, 10, 14, and 16—where
most oftheMediterraneanWD-causing mutationslie—have
a higher frequency in a group of patients aﬀe c t e db ym i l do r
moderate AD compared to a group of healthy individuals.
2.Materialsand Methods
190 patients with AD and 164 elderly controls were recruited
by two specialized dementia care centres: the Department
of Neuroscience, Fatebenefratelli Hospital, Isola Tiberina,
in Rome, and the Department of Neurology, Campus Bio-
Medico University, Rome, Italy, using a common standard-
ized clinical protocol [10].
The AD patients sample consisted of individuals with
a diagnosis of probable AD according to NINCDS-ADRDA
criteria[44,45]andanMMSEscoreof25orless[41].AllAD
patients underwent general medical, neurologic, and psy-
chiatric assessments. Neuroimaging diagnostic procedures
(magneticresonanceimagingorcomputedtomography)and
complete laboratory analyses were performed to exclude
other causes of progressive or reversible dementia. The con-
trol sample consisted of healthy volunteers with no clinical
evidence of neurological and psychiatric disease. Criteria
for exclusion of both patients and controls were conditions
known to aﬀect copper metabolism and biological variables
of oxidative stress (e.g., diabetes mellitus, inﬂammatory
diseases,recenthistory ofheartorrespiratoryfailure,chronic
liver or renal failure, malignant tumors, and a recent history
of alcohol abuse).
Among the study populations, 28 AD cases and 41
controls were not analyzed for c.1216 T>G and 10 cases and
13controlsforc.2495A>Gbecauseduringtheanalysesitwas
not possible to assess the genotype (insuﬃcient DNA/blood
sample, sequence analysis failure).
The study was approved by the local IRB, and all
participants or legal guardians signed an informed consent.
2.1. SNPs Genotyping. We collected approximately 10mL of
peripheral blood samples from study participants. Genomic
DNA from fresh whole blood was prepared using the
conventional method for DNA isolation (QLAamp DNA
Blood Midi kit).
Polymerase chain reaction (PCR) was performed to
amplify the exons and ﬂanking regions of the ATP7B gene.
DNA ampliﬁcation was carried out in a total volume of
25μL containing 50–100ng of genomic DNA, 10pmol of
each primer, 0.4mM of dNTPs, 3mMMgCl2, and 1 unit
of Taq polymerase (Taq Gold, Applied Biosystems) in a
thermocycler (2720 Thermal Cycler Applied Biosystem).
The conditions were denaturation at 95◦C for 30s, 30s of
appropriate annealing temperature (varying between 53◦C–
58◦C), and 30s of extension temperature at 72◦Cf o r3 0
cycles with 5min at 72◦Cﬁ n a le x t e n s i o n .P r i m e r s ,s e q u e n c e s
and annealing temperatures are reported in Table 1.
The PCR products that were free of contaminating bands
dueto nonspeciﬁc ampliﬁcationwere column-puriﬁed using
Nucleo Spin Extract II (Macherey-Nagel). Sequencing PCR
reaction was performed in atotalvolumeof20μL containing
2μL Terminator Ready Reaction mix (Applied Biosystems),
3.2pmol primers, 3μL Dilution Buﬀer, 6ng puriﬁed PCR
product.
Bidirectional sequencing of exons 2, 5, 8, 10, 14, and 16
of the ATP7B gene was performed using an ABI prism 310
DNA analyzer (Applied Biosystems) with dye-termination
chemistry.
Nucleotide changes were detected by comparing the
sequence obtained in the chromatogram with the normal
gene sequence [NG 008806.1; Homo sapiens ATPase, Cu++
transporting, betapolypeptide(ATP7B)on chromosome 13]
using SeqScape software version 2.5 (Applied Biosystems).
PCR-restriction fragment length polymorphism (RFLP)
assay was applied for detection of c.1216 T>G (rs1801243)
ATP7B SNP in AD and healthy controls (Figure 1). PCR-
RFLP reaction was the same as the one reported above
using speciﬁc oligonucleotide primers (Table 1). The T>G
transition at the exon 2 creates an MspA1I (Promega)
restriction-endonuclease recognition site. The 584bp PCR
product was digested with MspA1I only if the substitution
was present. MspA1I reactions were performed at 37◦Cf o r
2h 30min. All restriction products were analyzed on a 1.5%
agarose gel by electrophoresis and visualized by staining the
gel using ethidium bromide. Homozygous alleles of the TT
genotype appeared as a 584bp DNA band on the gel, and
homozygous alleles of the GG genotype appeared as a 375bp
and an 209bp DNA band. Heterozygote alleles displayed
a combination of the bands (584bp, 375bp and 209bp).
DirectDNAbidirectionalsequencingwasperformedfor15%
of the PCR products, which were randomly selected and
analyzed to conﬁrm the genotypes.
Detection of c.2495 A>G (rs1061472) ATP7B polymor-
phism was performed by direct bidirectional sequencing of
exon 10.
Bidirectionalsequencingofexon10wasperformed using
an ABI prism 310 DNA analyzer (Applied Biosystem, Foster
City CA) with dye-termination chemistry. PCR reaction wasInternational Journal of Alzheimer’s Disease 3
Table 1: Oligonucleotides sequences.
Primer forward for sequencing Primer reverse for sequencing Annealing
temperature
PCR
product
Exon 2a 5
  AGAGGCCGTCATCACTTATC 3  5
  CAATGGCAATCAGAGTGGTA 3
  57◦C 255bp
Exon 2b 5
  AGCTCCTAGGGGTTCAAAGT 3  5
  CAAGGAAAGTTTGCAGGATT 3
  57◦C 584bp
Exon 5 5
  TTTCACAGGCTTTCCTTGAT 3  5
  ATTTCCATGGGAAAAGTTGA 3
  53◦C 336bp
Exon 8 5
  CGACTGTGCACAAAGCTAGA 3  5
  CATGGTGTTCAGAGGAAGTG 3
  54◦C 386bp
Exon 10 5
  CAGCTGGCCTAGAACCTGAC 3  5
  TATCCTCCTGAGGGAACAT 3
  53◦C 234bp
Exon 14 5
  CTGTGCAGGTGTCTTGTTTC 3  5
  TTTTCCAGACCACACAGAGA 3
  57◦C 407bp
Exon 16 5
  TGTCCTAAAGGATGCTGTCA 3  5
  GGAAAACAGGCCTGAAATTA 3
  55◦C 451bp
Primer forward for allele-speciﬁc PCR Primer reverse for allele-speciﬁc PCR
Exon 10 5
  CAGCTGGCCTAGAACCTGACCC 3
  5
  GAAACTTTCCCCCAGGGACCACCT 3
 
5
  ACTTTCCCCCAGGGACCACCC 3
  63◦C 141bp
Beta actin 5
  GTCACATCCAGGGTCCTCAC 3
  5
  CACCTTCACCGTTCCAGTTT 3
  65◦C 350bp
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Figure 1: Analytical procedures for ATP7B SNPs detection. (a) PCR-restriction fragment length polymorphism (RFLP) assay for detection
of c.1216 T>G SNP. Lane 1:PCR 100bp low ladder. Lane 2:GG genotype (375bp and 209bp RFLP). Lane 3:TG genotype (584bp, 375bp
and 209bp RFLP). Lane 4:TT genotype (584bp RFLP). In the electropherogram the arrow indicates the TG genotype. (b) TaqMan allelic
discrimination assays for detection of c.2495 A>G SNP. Blue: AA genotype. Green: TG genotype. Red: GG genotype; x: undetermined.
the same as the one reported above. Oligonucleotides are
detailed in Table 1.
Genotyping of SNPs rs1061472 was achieved by the
TaqMan allelic discrimination assays from Applied Biosys-
tems Inc. (Foster City CA) (Figure 1). The predesigned
S N P sg e n o t y p i n ga s s a yI Di sI DC1919004 30 (Applied
Biosystems). The total reaction volume per well was 20μL,
including 5ng genomic DNA, 1μL TaqMan SNP genotyping
assay (containing two PCR primers and two dye (VIC or
FAM)-labelled TaqMan MGB probes) and 10μLT a q M a n
Universal PCR Master Mix (Applied Biosystems), according
to the manufacturer’s manual.
PCR was performed at 95◦C for 10min and 40 cycles
at 95◦C for 15s and 60◦C for 1min. The samples were
ampliﬁed, read, and analyzed using the ABI Prism 7900HT
SequenceDetection Systemand ABI Prism SDS2.4 software.
Two blank controls in each 96-well plate were used for the
assay quality control.
Apolipoprotein E (APOE) genotyping was performed
according to established methods [46].4 International Journal of Alzheimer’s Disease
Table 2: Demographic characteristics of the investigated groups.
Data are mean (SD).
AD patients Controls
Number of subjects 190 164
Sex F (%) 70 68
Education mean (SD) 9 (5.0) 9.3 (4.6)
Age (years) mean (SD) 74.4 (7.9)
a 67.7 (11.2)
MMSE mean (SD) 18.6 (5.8)
a 28.3 (1.2)
APOE ε4f r e q u e n c y ( % ) 3 5 a 13
∗Correlation is signiﬁcant at the 0.05 level (2-tailed).
aSigniﬁcantlydiﬀerent between AD and control group (P < .001).
bSigniﬁcantlydiﬀerent between AD and control group (P < .05).
2.2. Statistical Analyses. Demographic and clinical charac-
teristics in our patient and control samples were described
either in terms of mean ± SD if quantitative, or in terms of
proportions.
To calculate the power analysis of our study we consid-
ered data reported in general population (CEPH) [47, 48]o f
SNPs allele distribution. As the presence of TG heterozygosis
in healthy individuals was about 40% for c.1216 SNP and
that of AG heterozygosis was 52% for c.2945 SNP [47, 48],
we estimated that, with our sample size, the power was 80%
to recognize as signiﬁcant (at bilateral alpha level of 0.05) a
higher prevalence in AD with respect to controls of 12% (or
more) for c.1216 SNP and of 11% for c.2945 SNP.
After checking for normality, Student’s t-tests were used
when appropriate to evaluate diﬀerences in quantitative
variables. The diﬀerences in the overall distribution of the
alleles among normal and AD chromosomes were evaluated
by χ2 test. The association of the allele with the largest
positive deviation between the observed and the expected
frequency under null hypothesis was represented with a
2 × 2 table and tested by means of χ2 test. The relative
risk of having AD was estimated by Odds Ratios (ORs),
and corresponding 95% CIs were also provided. Two-sided
χ2 tests were used to verify Hardy-Weinberg equilibrium.
Logistic regression analysis with group (cases and con-
trols) as dependent variable and genetic and demographic
measures as independent variables allowed identifying the
characteristics more able to discriminate the two groups.
Coeﬃcient pairwise Linkage Disequilibrium (LD; D’)
between ATP 7B SNPs was estimated using Haploview
version 4.2 [49].
All analyses were conducted with SPSS software version
16.0 (SPSS Ltd., Surrey, UK). A P value less than.05 was
considered signiﬁcant in all statistical analysis.
3.Results
Main demographicand clinicalcharacteristics of thesubjects
participating to this study were reported in Table 2.A D
patients and controls did not diﬀer for sex, but diﬀered
in age, mean MMSE score, and APOE ε4 allele frequency
(Table 2). As the age eﬀect was considered a potentially
confoundingfactor,itwastakenintoaccountinthestatistical
analyses. As expected, the mean MMSE score was lower in
patients than in controls. Education did not diﬀer between
the2groups,while thepresenceofatleastoneAPOEε4allele
was more frequent in patients than in controls (OR = 3.7;
95% CI = 2.1–6.5; P < .001).
The genetic screening for WD mutations in the sole AD
cohort by direct sequencing was restricted to exons 2, 5, 8,
14, and 16 of the ATP7B gene in 180 chromosomes, while
it was carried out in 360 AD chromosomes and 302 control
chromosomes for exon 10. The study revealed no mutations,
but sequence changes corresponding to the c.1216 T>G
(Ser406Ala) in exon 2 and 2495 A>G (Lys832Arg) in exon
10 SNPs occurred.
The Hardy-Weinberg equilibrium was checked in each
group. No statistically signiﬁcant diﬀerences were found.
3.1. C.1216 T>G SNP (Exon 2) in AD and Healthy Controls.
Genotype frequencies of c.1216 T>G SNP in our control
panel were as follows: TT 30.9%, TG 49.6%, and GG 19.5%.
In AD patients they were not diﬀerent, being TT 24.1%,
TG 50.6%, and GG 25.3% (χ2 = 2.25, P = .325). Also allele
frequency did not diﬀer between groups (Table 3). When we
merged data of TG and TT genotype carriers together and
comparedtheirpooledfrequencyversusthatofGG genotype
in a model of logistic regression analysis taking into account
the age eﬀect, we observed a higher frequency of GG in
patients than in controls, although the diﬀerence was only
marginally signiﬁcant (OR = 1.773; 95% CI = 0.947–3.320;
P = .074; Table 3).
3.2. C.2495 A>G SNP (Exon 10) in AD and Healthy Controls.
c.2495 A>G genotype frequencies in our control panel
were as follows: AA 14.6%, AG 56.3%, and GG 29.1%.
In AD patients they were not diﬀerent, being AA 9.4%,
AG 57.1%, and GG 38.9%. The overall χ2 indicated that
the 2 distributions were not clearly diﬀerent (χ2 = 4.42,
P = .110), although the linear component (considering the
number ofG alleles:0,1,2)suggestedtherewas an association
(χ2 = 4.441, P = .036). G allele frequency was higher in
AD than in controls (χ2 = 3.8, P = .05). Furthermore, when
we merged data of AG and GG genotype carriers together
and compared their pooled frequency versus that of GG
genotype, in a model of logistic regression, GG category was
signiﬁcantly more frequent in AD patients than in controls
(Table 4). In particular, GG genotype was carried by 39% of
AD patients versus 29% of healthy controls and resulted in a
signiﬁcant odds ratio (OR = 1.741; 95% CI = 1.060–2.858;
P = .028).
Allele frequency of the 2 SNPs in our cohorts (Tables 3
and 4) resembles those reported in HapMap for European
origin populations.
To verify whether c.1216 T>G and c.2495 A>G SNPs
were in linkage disequilibrium (LD), we constructed plots
for our 2 cohorts and compared them with those reported in
HapMap database (http://www.hapmap.org/) for European
origin population (Figure 1). The analysis revealed that the 2
ATP7B SNPs were not in high LD in our population, eitherInternational Journal of Alzheimer’s Disease 5
Table 3: c.1216 T>G ATP7B (exon 2) SNP allele distribution in AD patients and healthy controls and comparison of GG versus TG+TT.
c.1216 T>GA T P 7 B
(exon 2)
AD patients
(162)
Controls
(123) P value
Allele T frequency n (%) 160 (49%) 137 (55.7%) χ2 = 2.23;df = 1;
P = .13 Allele G frequency n (%) 164 (51%) 109 (44.3%)
GG n (%) 41 (25.3%) 24 (19.5%) P = .074
∗
TG +TT n (%) 121 (74.7%) 99 (80.5%)
Correlation is signiﬁcant at the.05 level (2-tailed). ∗The analyseswere corrected for the age eﬀect.
Table 4: c.2495 A>G ATP7B (exon 10) SNP allele distribution in AD patients and healthy controls and comparison between GG versus
AG+ AA.
c.2495 A>GA T P 7 B
(exon 10) SNP
AD patients
(180) Controls (151) P value
Allele A frequency n (%) 127 (35%) 129 (43%) χ2 = 3.8;df = 1;
P = .05 Allele G frequency n (%) 233 (65%) 173 (57%)
GG n (%) 70 (39%) 44 (29%) P = .028
∗
AG+AA n (%) 110 (61%) 107 (71%)
Correlation is signiﬁcant at the.05 level (2-tailed). ∗The analyseswere corrected for the age eﬀect.
when analysing the subjects’ sample separately as an AD (D 
= 0.74; D’ conﬁdence bounds-Conf. Bounds-0.60–0.84 ) and
a control (D  value = 0.64; Conf. Bounds 0.5–0.77) cohort
or when considering the subjects as a combined population
(D  value = 0.70; Conf. Bounds 0.59–0.79). The degree of
LD calculated for the Italian Tuscan population (TSI; D 
= 90; Conf. Bounds 0.77–0.97) and for the Utah residents
with Northern and Western European ancestry from CEPH
collection (CEU; D  = 93; 0.85–0.98), on the basis of data
reported in HapMap database, was higher than that we
identiﬁed (Figure 2).
APOE ε4and ATP7B (bothc.1216T>Gand c.2495A>G)
SNPs were independent AD risk factors, since there was
no diﬀerence in the frequency of the ATP7B SNPs between
carriers and noncarriers of the APOE ε4 allele (consistently
P > .2), in addition to when the analysis was restricted to
assessment of only the AD population (consistently P > .2).
4.Discussion
We have focused the current investigation on ATP7B WD
gene, which is a tight control balance regulator for free
copper levels in the body [42, 43, 50]. ATPase 7B protein is
expressed at high levels in the liver and kidney and at lower
levels in the lung, placenta, and brain [50]. It is localized to
the trans-Golgi membrane where it maintains intracellular
copper concentration by transporting copper from the
cytosol across the Golgi lumen. In the Golgi lumen, ATPase
7B mediates the incorporation of copper atoms into ceru-
loplasmin during its biosynthesis [51–53]. Under elevated
copper concentrations ATPase 7B undergoes a reversible,
copper-mediated translocation from the trans-Golgi to the
apical canalicular membrane where it pumps copper directly
into the bile [51–56]. In WD, defects of ATPase 7B prevents
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Figure 2: Pairwise LDs are shown, calculated between the ATP7B
geneSNPsinAD, controls,wholesampleandinHapMapEuropean
origin populations (CEU: Utah residents with Northern and
WesternEuropean ancestry fromtheCEPH collection; TSI:Tuscans
in Italy). The top panel depicts the location of the SNPs in the
AT7PB gene. The intensity of the box shading is proportional to
the strength of the LD (D  conﬁdence bounds) for the marker pair,
which is also indicated as a percentage within each box.6 International Journal of Alzheimer’s Disease
copper translocation to the secretory pathway as well as the
excretion trough the bile, resulting in free copper increased
levels and in the secretion of apoceruloplasmin which, being
unstable, is rapidly degraded in the blood [54, 57]. In a
dedicated study, we have shown that a conspicuous amount
of apoceruloplasmin is present in the CSF of AD patients
[58]. We have also reported fragmentation of ceruloplasmin,
revealed by the presence of low-molecular-weight fragments
(<50 KDa) of ceruloplasmin in AD samples from selected
patients with higher-than-normal levels of free copper
[59].
The most common Mediterranean WD mutations were
reported to lie primary in exons 2, 5, 8, 10, 14, and 16
[47, 48, 60–68]. In particular, the Cys271Stop mutation
in exon 2 was reported to account for 19% of the total
mutations in the European and Turkish population [61].
1708-1 G>C, 1785 delT, and 1823 del3 have been identiﬁed
in the Italian population (exon 5) [62–65]. The 2299insC
mutation in exon 8 was found in Continental Italians [63].
In the same exon lies the Arg 778 Leu mutation, which is
the prevalent mutation of the Mongoloid population [60].
The 2464delC in exon 10 was found in Sardinian and the
2533delA in Sardinian, Continental Italian, Turkish, and
Albanian populations [62]. His1069Gln in exon 14, which
was reported to account for 17.5% of WD mutations in
Mediterraneans, was also found in 20–40% of the WD cases
in diﬀerent Caucasianpopulationgroups[47, 63, 65, 66, 68].
Val1146Met and Ile1148Thr in exon 16 have been identiﬁed
in Greek population [62–65]. Along with these relatively
common mutations, several other very rare mutations in
Mediterraneans have been described in the exons object of
our pilot investigation [62–65].
T h eA T P 7 Bg e n es e q u e n c ea n a l y s i so fe x o n s2 ,5 ,8 ,1 4 ,
16 in 180 AD chromosomes—and 662 chromosomes only
for exon 10—did not reveal any other sequence change than
c.1216 T>G and c.2495 A>G ATP7B SNPs. As a result we
focused our study on these 2 SNPs.
Our main observation is that c.2495 A>G ATP7B SNP as
either the G allele frequency or the rate of distribution of the
GG genotype is higher in AD patients than in healthy con-
trols. The c.1216 T>G SNP was also diﬀerently distributed
between AD and healthy controls but the signiﬁcance did
not reach the statistical threshold, probably because of the
small size of the patient’s sample analyzed. However, it
has to be noted that the potential role as AD risk factor
of the considered ATP7B SNPs could have been masked
by the diﬀerence of 7 years between our AD patients and
controls. In the attempt to reduce this potential confounder
we took into account an age eﬀect in our statistical analyses.
However, the possibility that some controls might convert
to AD while they age another 7 years makes controls and
cases more close to each other, and thus our estimate of the
statistical association between AD and these SNPs should be
considered conservative.
Genotypes and allele distributions for both SNPs found
in our panel were coherent with those reported in HapMap
for general populations of European origin [47, 48]. While
c.1216 T>G and c.2495 A>G SNPs are in LD in TSI and
in CEU samples, in our panel they resulted in a lower LD
degree.
Exon 2 encodes for a region containing metal-binding
domains in ATPase 7B protein. This region encompasses
amino acids 1-481. The genetic change in c.1216 T>G SNP
corresponds to a substitution ser 406 ala, within this region.
Exon10encodesforaregionwithin theATP bindingdomain
region in the protein which encompasses amino acids 820–
967. The genetic variation in c.2495 A>G corresponds to
a lys 832 arg substitution [43] within this region. Thus it
could be argued that these amino acids changes can have an
a disturbing eﬀect on ATPase7B function in terms of metal
binding properties or ATP hydrolysis which can eventually
result in copper homeostasis abnormalities.
This study has a number of limitations which includethe
small size of the sample, 7 years between cases and controls,
the restriction of the sequence analysis to a limited number
of ATP7B exons, the need for AD selection with possible
sampling bias, and surely it needs conﬁrmation in a larger
subject population (in progress). Despite these limitations,
this pilot investigation opens new routes—genetic rather
than biochemical—for the study of free copper deregulation
in AD and strengthens the concept that properly tuning
the redistribution of metals via metal complexing or ligand
agents, as successfully tested for WD, may positively aﬀect
the natural history of AD, at least for the ATP7B c.2495 GG
AD carriers [1, 28, 69].
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